Collaboration
with Impact
Contact an expert
Partnering with MImAbs gives you access to world-class antibody expertise, agile and customized programs, and deep scientific insight all with a strict commitment to data confidentiality. Your intellectual property remains fully yours, supported by a transparent and rigorous IP policy. We work closely by your side to accelerate discovery and drive therapeutic success.
Integrated Programs
We design and deliver comprehensive programs starting from your target of interest, managing each step to meet your objectives. Our integrated approach focuses on de-risking at every stage, while optimizing time and cost to ensure robust and reliable results.
Tailored activities
From discovery to optimization, production or characterization, we adapt to your needs. Our expertise allows us to propose the most relevant options and guide you with flexibility and precision throughout your project.
Discover the steps of our expertise
Project analysis
Expert advice and development plans to set your antibody project on the right path.
mAb Generation
Efficient antigen/mRNA immunisation and single B cell screening for lead discovery.
mAb Engineering
Humanization and multispecific designs to optimize developability and function.
Bioproduction
Scalable production up to 400mg with conjugate characterization and formulation.
Pharmacology
In vitro and in vivo assays to evaluate efficacy, toxicity and immune profiling.
Dedicated resources for your program
Our collaboration model is built on FTE-based partnerships with dedicated resources, structured workplans, and scientific guidance from the outset. Together, we design and execute antibody discovery and development strategies that align with your objectives. Our commitment: consistent support, expert guidance, and reliable outcomes at every stage of your project.
Years of proven expertise
With over 20 therapeutic antibody programs delivered and 7 antibodies in clinical development, MImAbs partners with innovative biotechs such as Emergence Therapeutics (acquired by Eli Lilly in 2023) and Adcytherix (€105M raised in 2025). Our expertise in antibody and conjugate discovery drives smarter, de-risked strategies and tangible translational impact.
Transparent IP Policy
All intellectual property generated during our collaborations remains the full property of our clients. MImAbs conducts no proprietary drug discovery program, guaranteeing your complete ownership and freedom to operate. Our strong commitment and rules to confidentiality ensure your serenity while developing innovative programs.
Would you like to explore a partnership with MImAbs?
Contact MImAbs to discuss your project, our team will support you in the scientific study and strategic development planning of your project.
Contact an expert